Corium International, Inc. (NASDAQ:CORI) major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $11.05, for a total transaction of $1,657,500.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Healthcare Master Fun Broadfin also recently made the following trade(s):
- On Wednesday, October 4th, Healthcare Master Fun Broadfin sold 218,100 shares of Corium International stock. The shares were sold at an average price of $11.01, for a total transaction of $2,401,281.00.
Corium International, Inc. (NASDAQ CORI) opened at $10.69 on Tuesday. The company has a quick ratio of 6.80, a current ratio of 7.04 and a debt-to-equity ratio of 1.89. Corium International, Inc. has a 12 month low of $2.67 and a 12 month high of $11.37.
WARNING: “Corium International, Inc. (NASDAQ:CORI) Major Shareholder Healthcare Master Fun Broadfin Sells 150,000 Shares” was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.truebluetribune.com/2017/11/14/healthcare-master-fun-broadfin-sells-150000-shares-of-corium-international-inc-cori-stock.html.
A number of institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its position in Corium International by 33.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 22,285 shares during the last quarter. California State Teachers Retirement System acquired a new stake in Corium International in the 2nd quarter valued at approximately $263,000. State Street Corp acquired a new position in shares of Corium International during the 2nd quarter worth approximately $1,840,000. Stonepine Capital Management LLC acquired a new position in shares of Corium International during the 2nd quarter worth approximately $3,085,000. Finally, EAM Investors LLC acquired a new position in shares of Corium International during the 2nd quarter worth approximately $563,000. 90.25% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have issued reports on CORI shares. Jefferies Group LLC restated a “buy” rating and set a $8.00 price objective on shares of Corium International in a report on Wednesday, July 19th. BidaskClub upgraded Corium International from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Zacks Investment Research cut Corium International from a “buy” rating to a “sell” rating in a research note on Tuesday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 target price on shares of Corium International in a research report on Sunday, September 17th. Finally, ValuEngine cut Corium International from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $13.00.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.